We are live on ! Find out more
ELEV

Elevation Oncology
ELEV

Delisted

ELEV was delisted on the 22nd of July, 2025.

Back to rankings

27 hedge funds and large institutions have $13.7M invested in Elevation Oncology in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

8% more funds holding

Funds holding: 25 → 27 (+2)

0.6% more ownership

Funds ownership: 61.31% → 61.91% (+0.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

15% less capital invested

Capital invested by funds: $16.1M → $13.7M (-$2.44M)

Holders
27
Holders Change
+2
Holders Change %
+8%
% of All Funds
0.43%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
5
Increased
5
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$487K
2
AC
Annandale Capital
Texas
+$20.3K
3
JP Morgan Chase
JP Morgan Chase
New York
+$4.3K
4
UBS Group
UBS Group
Switzerland
+$1.81K
5
BlackRock
BlackRock
New York
+$686

Top Sellers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
-$271K
2
Renaissance Technologies
Renaissance Technologies
New York
-$90.1K
3
MAM
Marquette Asset Management
Minnesota
-$44K
4
TRCT
Tower Research Capital (TRC)
New York
-$6.22K
5
Osaic Holdings
Osaic Holdings
Arizona
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Aisling Capital Management
New York
$2.69M – – –
QUSVM
2
Qiming U.S. Ventures Management
Washington
$2.25M – – –
BI
3
BVF Inc
California
$2.19M – – –
CAM
4
Cormorant Asset Management
Massachusetts
$1.85M – – –
VP
5
venBio Partners
California
$1.77M – – –
SB
6
Samsara BioCapital
California
$789K – – –
TCM
7
Tang Capital Management
California
$456K +$487K +479,854 New
SCM
8
Sio Capital Management
New York
$342K – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$317K +$288 +284 +0.1%
TCM
10
TCG Crossover Management
California
$274K -$271K -266,610 -48%
Renaissance Technologies
11
Renaissance Technologies
New York
$190K -$90.1K -88,757 -31%
KCM
12
Kennedy Capital Management
Missouri
$142K – – –
BCM
13
Bridgeway Capital Management
Texas
$127K – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$85K -$288 -284 -0.3%
CC
15
Caxton Corporation
New Jersey
$64.8K +$27 +27 +0%
AC
16
Annandale Capital
Texas
$48K +$20.3K +20,000 +67%
BCM
17
BML Capital Management
Indiana
$38K +$40.6K +39,963 New
BlackRock
18
BlackRock
New York
$35.7K +$686 +676 +2%
State Street
19
State Street
Massachusetts
$17.5K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$4K +$4.3K +4,240 New
UBS Group
21
UBS Group
Switzerland
$1.69K +$1.81K +1,782 New
TRCT
22
Tower Research Capital (TRC)
New York
$1K -$6.22K -6,125 -88%
SPIA
23
Steward Partners Investment Advisory
New York
$475 – – –
Barclays
24
Barclays
United Kingdom
$372 – – –
Morgan Stanley
25
Morgan Stanley
New York
$109 – – –
1
2

ELEV Hedge Fund Activity: Q4 2022 in Review

27 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q4 2022, worth a combined $13.7M — down 15% from $16.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ELEV positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $487K. The largest seller was TCG Crossover Management, cutting an estimated $271K.

  • 27 institutional investors held Elevation Oncology (ELEV) as of Q4 2022, up from 25 in Q3 2022.
  • Funds reported $13.7M of Elevation Oncology stock for Q4 2022, down 15% quarter-over-quarter.
  • 5 funds opened new Elevation Oncology positions in Q4 2022 and 3 closed out, a net change of +2 holders.
  • The largest Elevation Oncology buyer in Q4 2022 was Tang Capital Management, an estimated $487K added.
  • The largest Elevation Oncology seller in Q4 2022 was TCG Crossover Management, an estimated $271K sold.

Based on aggregated 13F filings for Q4 2022.